Education
About Us
Working with TipRanks
Follow Us
Compass Therapeutics (CMPX)
NASDAQ:CMPX
Total Valuation
Compass Therapeutics has a market cap or net worth of $261.35M. The enterprise value is $79.75M.
Market Cap$261.35M
Enterprise Value$79.75M
Share Statistics
Compass Therapeutics has 138,282,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding138,282,500
Owned by Insiders27.23%
Owned by Institutions0.04%
Financial Efficiency
Compass Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -33.51%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-33.51%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee0.00
Profits Per Employee-1.21M
Employee Count35
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Compass Therapeutics is -4.66. Compass Therapeutics’s PEG ratio is 0.82.
PE Ratio-4.66
PS Ratio0.00
PB Ratio1.33
Price to Fair Value1.33
Price to FCF-4.88
Price to Operating Cash Flow-4.88
PEG Ratio0.82
Income Statement
In the last 12 months, Compass Therapeutics had revenue of 0.00 and earned -42.49M in profits. Earnings per share was -0.33.
Revenue0.00
Gross Profit-1.89M
Operating Income-50.36M
Pretax Income-42.49M
Net Income-42.49M
EBITDA-48.47M
Earnings Per Share (EPS)-0.33
Cash Flow
In the last 12 months, operating cash flow was -48.05M and capital expenditures -53.00K, giving a free cash flow of -48.10M billion.
Operating Cash Flow-48.05M
Free Cash Flow-48.10M
Free Cash Flow per Share-0.35
Dividends & Yields
Compass Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.02
52-Week Price Change9.41%
50-Day Moving Average2.18
200-Day Moving Average1.88
Relative Strength Index (RSI)47.69
Average Volume (3m)2.07M
Important Dates
Compass Therapeutics upcoming earnings date is May 12, 2025, TBA Not Confirmed.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 12, 2025
Ex-Dividend Date―
Financial Position
Compass Therapeutics as a current ratio of 19.73, with Debt / Equity ratio of 4.97%
Current Ratio19.73
Quick Ratio19.73
Debt to Market Cap<0.01
Net Debt to EBITDA0.46
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Compass Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Compass Therapeutics EV to EBITDA ratio is -3.62, with an EV/FCF ratio of -4.32.
EV to Sales0.00
EV to EBITDA-3.62
EV to Free Cash Flow-4.32
EV to Operating Cash Flow-4.32
Balance Sheet
Compass Therapeutics has $135.40M in cash and marketable securities with $1.41M in debt, giving a net cash position of -$128.53M billion.
Cash & Marketable Securities$135.40M
Total Debt$1.41M
Net Cash-$128.53M
Net Cash Per Share-$0.93
Tangible Book Value Per Share$1.17
Margins
Gross margin is 74.80%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin74.80%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Compass Therapeutics is $12.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$12.17
Price Target Upside543.92% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast-7.93%